{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T04:14:58Z","timestamp":1790309698548,"version":"4.1.0"},"reference-count":138,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am Soc Clin Oncol Educ Book"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>The treatment paradigm of stage II to III triple-negative breast cancer (TNBC) is rapidly evolving, with the recent incorporation of pembrolizumab to neoadjuvant chemotherapy improving disease outcomes. Nevertheless, almost one in five patients with early-stage TNBC will relapse in 5 years, underscoring an urgent need to identify and improve outcomes for those at high risk of recurrence. Novel therapeutic strategies including antibody-drug conjugates, anti-vascular endothelial growth factor therapies, dual immune checkpoint blockade, and locoregional therapies to augment the antitumor immune response are being investigated in clinical trials. Biomarker strategies including tumor infiltrating lymphocytes, immune signatures, and circulating tumor DNA are being explored to identify patients at a high risk of relapse and to predict treatment response. In this article, we review recent advances in the management of stage II to III TNBC, highlight emerging investigational therapies and combinations, and explore novel biomarker strategies aimed at personalizing the care for patients with stage II to III TNBC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/edbk-26-520834","type":"journal-article","created":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T19:59:30Z","timestamp":1776369570000},"source":"Crossref","is-referenced-by-count":3,"title":["Personalizing Curative Therapy in Stage II to III Triple-Negative Breast Cancer"],"prefix":"10.1200","volume":"46","author":[{"given":"Alexis","family":"LeVee","sequence":"first","affiliation":[{"name":"Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maeve A.","family":"Hennessy","sequence":"additional","affiliation":[{"name":"Section of Hematology\/Oncology, Department of Medicine, University of Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dame","family":"Idossa","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Oncology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto A.","family":"Leon-Ferre","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Oncology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Nanda","sequence":"additional","affiliation":[{"name":"Section of Hematology\/Oncology, Department of Medicine, University of Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0201-3871","authenticated-orcid":false,"given":"Heather","family":"McArthur","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, University of Texas Southwestern Medical Center, Dallas, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-3045"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910549"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2112651"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2409932"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31953-X"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03725-4"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1158\/1557-3265.SABCS24-GS3-05"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.02.004"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.10.009"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz158"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.07.1940"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00757-5"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.23560"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-47910-1"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmorw.2024.100061"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-024-16390-7"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1158\/1557-3265.SABCS24-PS5-03"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2025.104473"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djx063"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.2493"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-017-0242-5"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010065"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-025-01185-x"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyaf371"},{"key":"e_1_3_2_26_2","unstructured":"US Food and Drug Administration: FDA approves new dosing regimen for pembrolizumab. 2020. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-new-dosing-regimen-pembrolizumab"},{"key":"e_1_3_2_27_2","article-title":"A phase II, randomized, open-label study to evaluate low-dose pembrolizumab plus chemotherapy vs chemotherapy as neoadjuvant therapy for localized triple negative breast cancer (TNBC). (PLANeT trial\u2014Pembrolizumab low dose in addition to NACT in TNBC)","author":"Arora A","unstructured":"Arora A, Bhaskarane H, Tansir G, et al: A phase II, randomized, open-label study to evaluate low-dose pembrolizumab plus chemotherapy vs chemotherapy as neoadjuvant therapy for localized triple negative breast cancer (TNBC). (PLANeT trial\u2014Pembrolizumab low dose in addition to NACT in TNBC). Ann Oncol 10.1016\/j.annonc.2025.12.015 [epub ahead of print on December 22, 2025]","journal-title":"Ann Oncol"},{"key":"e_1_3_2_28_2","doi-asserted-by":"crossref","unstructured":"Felsheim B Nekljudova V Carey LA et al: RF2-02: CALGB 40603; GeparSixto; BrighTNess-pooled analysis of the BrighTNess CALGB 40603 (Alliance) and GeparSixto clinical trials identifies the impact of neoadjuvant carboplatin on pCR and survival in early-stage triple-negative breast cancer. Presented at: San Antonio Breast Cancer Symposium; December 9 2025; San Antonio TX","DOI":"10.1158\/1557-3265.SABCS25-RF2-02"},{"key":"e_1_3_2_29_2","unstructured":"Reference deleted"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-01023"},{"key":"e_1_3_2_31_2","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA502","article-title":"A randomized, multicenter, open-label, phase III trial comparing anthracyclines followed by taxane versus anthracyclines followed by taxane plus carboplatin as (neo) adjuvant therapy in patients with early triple-negative breast cancer: Korean Cancer Study Group BR 15-1 PEARLY trial","volume":"42","author":"Sohn J","year":"2024","unstructured":"Sohn J, Kim GM, Jung KH, et al: A randomized, multicenter, open-label, phase III trial comparing anthracyclines followed by taxane versus anthracyclines followed by taxane plus carboplatin as (neo) adjuvant therapy in patients with early triple-negative breast cancer: Korean Cancer Study Group BR 15-1 PEARLY trial. J Clin Oncol 42, 2024 (suppl 17; abstr LBA502)","journal-title":"J Clin Oncol"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2025-085457"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.17_suppl.LBA509"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.2965"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-02412"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00285-4"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.71.4147"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2023.5033"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2511734"},{"key":"e_1_3_2_40_2","doi-asserted-by":"crossref","unstructured":"Dent R Shao Z Schmid P et al: First-line datopotamab deruxtecan (Dato-DXd) vs chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC) for whom immunotherapy was not an option: Primary results from the randomised phase 3 TROPION-Breast02 trial. Presented at: 2025 ESMO Congress; October 17 2025; Berlin Germany. Abstract LBA21","DOI":"10.1016\/j.annonc.2025.09.031"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.17_suppl.LBA109"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03267-1"},{"key":"e_1_3_2_43_2","doi-asserted-by":"crossref","unstructured":"Yam C Iwase T Nelson B et al: PS4-12-26: Neosaci-io: Neoadjuvant sacituzumab govitecan (sg) + pembrolizumab (pb) in patients (pts) with early-stage TNBC experiencing suboptimal response to keynote-522. Presented at: San Antonio Breast Cancer Symposium; December 9 2025; San Antonio TX","DOI":"10.1158\/1557-3265.SABCS25-PS4-12-26"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1038\/s12276-020-00500-y"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24043226"},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-020-01362-y"},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-021-00287-9"},{"key":"e_1_3_2_48_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-30569-0"},{"key":"e_1_3_2_49_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-022-01536-6"},{"key":"e_1_3_2_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2022.05.014"},{"key":"e_1_3_2_51_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03734-3"},{"key":"e_1_3_2_52_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-025-02337-1"},{"key":"e_1_3_2_53_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.e12600"},{"key":"e_1_3_2_54_2","doi-asserted-by":"publisher","DOI":"10.1158\/1557-3265.SABCS24-PS3-08"},{"key":"e_1_3_2_55_2","doi-asserted-by":"publisher","DOI":"10.1158\/1557-3265.SABCS24-PS3-05"},{"key":"e_1_3_2_56_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-1218"},{"key":"e_1_3_2_57_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-38534-6"},{"key":"e_1_3_2_58_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30324-7"},{"key":"e_1_3_2_59_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.1029"},{"key":"e_1_3_2_60_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2021.05.009"},{"key":"e_1_3_2_61_2","doi-asserted-by":"publisher","DOI":"10.1158\/1557-3265.SABCS25-RF5-02"},{"key":"e_1_3_2_62_2","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.24867"},{"key":"e_1_3_2_63_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-2182"},{"key":"e_1_3_2_64_2","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003776"},{"key":"e_1_3_2_65_2","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.SABCS22-GS5-03"},{"key":"e_1_3_2_66_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03249-3"},{"key":"e_1_3_2_67_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-021-06408-z"},{"key":"e_1_3_2_68_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32599"},{"key":"e_1_3_2_69_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.00003"},{"key":"e_1_3_2_70_2","doi-asserted-by":"publisher","DOI":"10.1016\/bs.mcb.2025.03.005"},{"key":"e_1_3_2_71_2","doi-asserted-by":"crossref","unstructured":"McArthur H Page D Rice S et al: PD7-07: Three-year event-free survival from a phase 2 study of peri-operative immune checkpoint inhibition and cryoablation in women with hormone receptor-negative HER2-negative early stage\/resectable breast cancer (ipilimumab\/nivolumab cohort). Presented at: San Antonio Breast Cancer Symposium; December 9 2025; San Antonio TX","DOI":"10.1158\/1557-3265.SABCS25-PD7-07"},{"key":"e_1_3_2_72_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-3492"},{"key":"e_1_3_2_73_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.10.008"},{"key":"e_1_3_2_74_2","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-009722"},{"key":"e_1_3_2_75_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2211437"},{"key":"e_1_3_2_76_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.26886"},{"key":"e_1_3_2_77_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.08.005"},{"key":"e_1_3_2_78_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.02.002"},{"key":"e_1_3_2_79_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1612645"},{"key":"e_1_3_2_80_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.1033"},{"key":"e_1_3_2_81_2","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000173"},{"key":"e_1_3_2_82_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2105215"},{"key":"e_1_3_2_83_2","doi-asserted-by":"crossref","unstructured":"Garber J Cameron D Campbell C et al: SESS-1568: OlympiA- phase 3 multicenter randomized placebo-controlled trial of adjuvant olaparib after (neo)adjuvant chemotherapy in patients w\/germline BRCA1\/BRCA2 pathogenic variants C high risk HER2-negative primary breast cancer; longer term follow-up. Presented at: San Antonio Breast Cancer Symposium; December 10 2024; San Antonio TX","DOI":"10.1158\/1557-3265.SABCS24-GS1-09"},{"key":"e_1_3_2_84_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32531-9"},{"key":"e_1_3_2_85_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-1773"},{"key":"e_1_3_2_86_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djab108"},{"key":"e_1_3_2_87_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1713444"},{"key":"e_1_3_2_88_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaf1490"},{"key":"e_1_3_2_89_2","doi-asserted-by":"publisher","DOI":"10.1158\/1557-3265.SABCS24-LB1-07"},{"key":"e_1_3_2_90_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.05.015"},{"key":"e_1_3_2_91_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.01010"},{"key":"e_1_3_2_92_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.3056"},{"key":"e_1_3_2_93_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0115103"},{"key":"e_1_3_2_94_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.01.072"},{"key":"e_1_3_2_95_2","doi-asserted-by":"crossref","unstructured":"Johannes H Schneeweiss A Frickel N et al: RF2-01: Prognostic markers in residual tumors after neoadjuvant chemotherapy (NACT) for early triple-negative breast cancer (TNBC)\u2014A pooled analysis from nine neoadjuvant GBG\/AGO-B trials. Presented at: San Antonio Breast Cancer Symposium; December 9 2025; San Antonio TX","DOI":"10.1158\/1557-3265.SABCS25-RF2-01"},{"key":"e_1_3_2_96_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.08.752"},{"key":"e_1_3_2_97_2","doi-asserted-by":"publisher","DOI":"10.1158\/1557-3265.SABCS25-PS4-10-26"},{"key":"e_1_3_2_98_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-69965-1"},{"key":"e_1_3_2_99_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-1323"},{"key":"e_1_3_2_100_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.08.149"},{"key":"e_1_3_2_101_2","doi-asserted-by":"crossref","unstructured":"Stabellini N Parthasarathy P Gautam I et al: PD7-01: Circulating determinants of response to immunotherapy in triple negative breast cancer (TNBC). Presented at: San Antonio Breast Cancer Symposium; December 9 2025; San Antonio TX","DOI":"10.1158\/1557-3265.SABCS25-PD7-01"},{"key":"e_1_3_2_102_2","unstructured":"Yam C Radko A Huo L et al: PD7-03: Circulating immune correlates of pathological response to neoadjuvant pembrolizumab plus chemotherapy in high-risk early-stage triple-negative breast cancer. Radko presented at: San Antonio Breast Cancer Symposium; December 9 2025; San Antonio TX"},{"key":"e_1_3_2_103_2","doi-asserted-by":"publisher","DOI":"10.1158\/1557-3265.SABCS25-PD7-02"},{"key":"e_1_3_2_104_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-06498-3"},{"key":"e_1_3_2_105_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-0149"},{"key":"e_1_3_2_106_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.514"},{"key":"e_1_3_2_107_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-017-0028-4"},{"key":"e_1_3_2_108_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-65432-5"},{"key":"e_1_3_2_109_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-57988-z"},{"key":"e_1_3_2_110_2","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aab0021"},{"key":"e_1_3_2_111_2","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aax7392"},{"key":"e_1_3_2_112_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.08.004"},{"key":"e_1_3_2_113_2","doi-asserted-by":"crossref","unstructured":"Loi S Niman SM Zdenkowski N et al: PD7-10: Neo-n (neon): Three-year event-free survival and ultrasensitive ctDNA dynamics in early triple-negative breast cancer (tnbc) treated with neoadjuvant carboplatin\/paclitaxel and nivolumab. Presented at: San Antonio Breast Cancer Symposium; December 9 2025","DOI":"10.1158\/1557-3265.SABCS25-PD7-10"},{"key":"e_1_3_2_114_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.11.007"},{"key":"e_1_3_2_115_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-46961-x"},{"key":"e_1_3_2_116_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.11.005"},{"key":"e_1_3_2_117_2","doi-asserted-by":"publisher","DOI":"10.1158\/1557-3265.SABCS24-GS3-01"},{"key":"e_1_3_2_118_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.medmic.2025.100155"},{"key":"e_1_3_2_119_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.217123"},{"key":"e_1_3_2_120_2","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyad060"},{"key":"e_1_3_2_121_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41418-021-00784-1"},{"key":"e_1_3_2_122_2","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2024-1423"},{"key":"e_1_3_2_123_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.593"},{"key":"e_1_3_2_124_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.1038"},{"key":"e_1_3_2_125_2","first-page":"4","article-title":"Profiling the gut and oral microbiota of hormone receptor-positive, HER2-negative metastatic breast cancer patients receiving pembrolizumab and eribulin","volume":"4","author":"Teng NM","year":"2025","unstructured":"Teng NM, Malfettone A, Dalby MJ, et al: Profiling the gut and oral microbiota of hormone receptor-positive, HER2-negative metastatic breast cancer patients receiving pembrolizumab and eribulin. Microbiome Res Rep 4:4, 2025","journal-title":"Microbiome Res Rep"},{"key":"e_1_3_2_126_2","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.SABCS22-PD11-05"},{"key":"e_1_3_2_127_2","doi-asserted-by":"publisher","DOI":"10.18383\/j.tom.2016.00247"},{"key":"e_1_3_2_128_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-020-00203-7"},{"key":"e_1_3_2_129_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2019.10.002"},{"key":"e_1_3_2_130_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-66220-9"},{"key":"e_1_3_2_131_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-025-00839-3"},{"key":"e_1_3_2_132_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.08.749"},{"key":"e_1_3_2_133_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-025-01012-6"},{"key":"e_1_3_2_134_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-023-01752-y"},{"key":"e_1_3_2_135_2","doi-asserted-by":"publisher","DOI":"10.1097\/RLI.0000000000000518"},{"key":"e_1_3_2_136_2","article-title":"Predicting response of triple-negative breast cancer to neoadjuvant chemotherapy using a deep convolutional neural network\u2013based artificial intelligence tool","author":"Krishnamurthy S","unstructured":"Krishnamurthy S, Jain P, Tripathy D, et al: Predicting response of triple-negative breast cancer to neoadjuvant chemotherapy using a deep convolutional neural network\u2013based artificial intelligence tool. JCO Clin Cancer Inform 10.1200\/CCI.22.00181","journal-title":"JCO Clin Cancer Inform"},{"key":"e_1_3_2_137_2","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics14010074"},{"key":"e_1_3_2_138_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2020.511071"},{"key":"e_1_3_2_139_2","article-title":"Imaging- and tumor biomarker-based multivariable model for early prediction of pathologic complete response to neoadjuvant systemic therapy in triple-negative breast cancer","author":"Adrada BE","unstructured":"Adrada BE, Guirguis MS, Huo L, et al: Imaging- and tumor biomarker-based multivariable model for early prediction of pathologic complete response to neoadjuvant systemic therapy in triple-negative breast cancer. JCO Precis Oncol 10.1200\/PO-25-00410","journal-title":"JCO Precis Oncol"}],"container-title":["American Society of Clinical Oncology Educational Book"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/EDBK-26-520834","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T19:59:35Z","timestamp":1776369575000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/EDBK-26-520834"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":138,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1200\/EDBK-26-520834"],"URL":"https:\/\/doi.org\/10.1200\/edbk-26-520834","relation":{},"ISSN":["1548-8748","1548-8756"],"issn-type":[{"value":"1548-8748","type":"print"},{"value":"1548-8756","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6]]},"article-number":"e520834"}}